Key Insights
- Strategic Expansion: Juvenescence acquires AI drug discovery firm Ro5 to supercharge its pipeline targeting age-related diseases.
- M42 Alliance Strengthens: Deal reinforces Abu Dhabi-based M42 partnership, following a $76M Series B-1 financing round.
- AI-Powered Healthspan Innovation: Integration of Ro5’s proprietary platform accelerates AI-based therapeutic discovery in cognition, cardio-metabolism, immunity, and cellular repair.
Juvenescence Acquires Ro5 to Bolster AI Capabilities in Drug Discovery
Juvenescence Limited, a clinical-stage AI-enabled biotech company, has acquired Ro5 Inc., an AI drug discovery innovator, to strengthen its R&D and expand its therapeutic pipeline. This move comes on the heels of a $76 million Series B-1 funding round led by M42, an Abu Dhabi-based healthcare giant. The acquisition provides Juvenescence access to Ro5’s powerful Biomedical Knowledge Graph with over 85 million nodes and 400 million relationships, enabling accelerated drug target discovery.
Ro5’s AI Platform to Accelerate Next-Gen Therapeutic Development
Ro5 brings a state-of-the-art AI Chemistry Platform that merges advanced machine learning and cheminformatics tools. This platform significantly reduces time from compound identification to lead optimization, enabling fast, accurate, and cost-efficient drug development. Now embedded within Juvenescence, Ro5’s technology is poised to amplify the development of AI-powered medicines designed to treat age-associated disorders.
Deal Deepens Strategic Partnership with M42 to Build Global Life Sciences Hub
The acquisition marks a key milestone in Juvenescence’s strategic alignment with M42. The companies are collaboratively working to establish a world-class life sciences hub in Abu Dhabi, focusing on AI-enabled biopharma innovation. This partnership not only aims to transform therapeutic development but also positions Abu Dhabi as a global epicenter for longevity-focused biotechnology.
Future-Focused Pipeline Targets Cognition, Cardio-Metabolism, and Cellular Repair
With Ro5’s AI-driven technologies integrated into its drug discovery processes, Juvenescence will accelerate the clinical development of therapeutics in key areas such as cognition, cardio-metabolism, immunity, and cellular regeneration. The company continues to push the boundaries of aging science by focusing on the root mechanisms of age-related diseases—underscoring its mission to extend healthy lifespan through cutting-edge biotechnology.
About Juvenescence
Juvenescence is a clinical-stage biotech company powered by AI, dedicated to developing breakthrough therapies that extend human healthspan. Founded by industry veterans with a proven track record in billion-dollar biopharma deals, the company focuses on aging-related diseases through a robust AI-integrated R&D platform. Learn more at www.JuvLabs.com
About Ro5
Ro5 is a next-generation AI drug discovery company leveraging proprietary neural network architectures and a Biomedical Knowledge Graph to expedite and enhance drug development. The company’s mission is to radically shorten timelines and costs while increasing precision in therapeutic discovery.
By
